logo

Biocryst Pharmaceuticals Inc (BCRX)



Trade BCRX now with
  Date
  Headline
6/9/2022 7:23:09 AM BioCryst Selects Pint Pharma As Commercial Partner For ORLADEYO In Latin America
4/5/2022 7:41:26 AM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/4/2021 7:29:02 AM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/20/2021 7:09:03 AM BioCryst Appoints Amy McKee To Board
6/16/2021 7:08:23 AM BioCryst Pharma: Israeli Ministry Of Health Accepts Regulatory Submission Of ORLADEYO
6/3/2021 7:13:40 AM BioCryst Says Oral, Once-daily ORLADEYO Is Now Available For Patients With Prescription In Germany
3/2/2021 7:15:34 AM BioCryst Submits MAA To UK’s MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema
2/3/2021 7:20:34 AM BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB
1/22/2021 7:04:42 AM BioCryst Secures Approval Of ORLADEYO In Japan
1/6/2016 6:06:29 AM Jefferies Is Cutting Biocryst Pharmaceuticals Inc (BCRX) 2016 Estimate To -0.54 From -0.41
1/6/2016 6:03:30 AM Jefferies Ups Biocryst Pharmaceuticals Inc (BCRX) To Buy From Hold With $14 Price Target